Search - tctmd.com

Displaying 321 - 340 of 821

Sort: Relevancy | Date

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

News Daily News

Risk Prediction Model Personalizes Revascularization Options for FREEDOM-Like Patients

Michael O'Riordan

October 17, 2019

Recurrent Events Common Among Young Patients With CAD

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

News Daily News

Dramatic Swings in Household Income Linked to CVD Risk: ARIC

Michael O'Riordan

October 09, 2019

News Conference News

Former EXCEL Investigator Alleges Trial Manipulation, Prompting Vehement Denials

Michael O'Riordan

October 07, 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

October 03, 2019

News Conference News TCT 2019

GLOBAL LEADERS Post Hoc: Okay to Drop Aspirin After 1 Month in ACS Patients?

September 30, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

September 29, 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

News Conference News TCT 2019

Leave It Be: PCI for Stable CAD Before or With TAVR Does Not Lower Mortality Risk

Michael O'Riordan

September 29, 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

News Conference News TCT 2019

New COMPLETE Data Affirm Benefit of Nonculprit PCI in STEMI Regardless of Timing

September 28, 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

September 26, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

News Conference News TCT 2019

Strokes Increasing in STEMI Patients With Cardiogenic Shock

September 25, 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

News Conference News ESC 2019

Young MI Patients’ Ischemic Risk Extends at Least Two Decades

September 06, 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

News Conference News ESC 2019

Transfer for Primary PCI Still Better Than Fibrinolysis After 16 Years: DANAMI-2

September 04, 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

News Conference News ESC 2019

Another Step Forward for Genotype-Guided Prescribing After PCI: POPular Genetics

Yael L. Maxwell

September 03, 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

News Conference News ESC 2019

Prasugrel Bests Ticagrelor in ACS Patients Heading to PCI: ISAR-REACT 5

September 01, 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

News Conference News ESC 2019

COMPLETE Beats Culprit-Only PCI in Multivessel STEMI and Timing Doesn’t Matter

Yael L. Maxwell

September 01, 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

News Conference News ESC 2019

POPULAR AGE Supports Clopidogrel Over Ticagrelor in Elderly ACS Patients

Michael O'Riordan

August 31, 2019

Decline in US Deaths From CVD and Diabetes Is Leveling Off

News Daily News

Decline in US Deaths From CVD and Diabetes Is Leveling Off

August 27, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.